Male occult breast cancer: one case report

doi:10.3877/cma.j.issn.1674-0807.2026.01.009

Abstract

Yangyang Zhong, Shuyao Deng, Yongjie Li. Male occult breast cancer: one case report[J]. Chinese Journal of Breast Disease(Electronic Edition), 2026, 20(01): 60-63.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2026.01.009

https://zhrxbzz.cma-cmc.com.cn/EN/Y2026/V20/I01/60

Figures/Tables 8

References 18

［1］	He M，Tang LC，Yu KD，et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer ［J］. Eur J Surg Oncol EJSO，2012，38（11）：1022-1028.
［2］	Sah AK，Choudhary RK，Sabrievna VA，et al. Male breast cancer：epidemiology，diagnosis，molecular mechanisms，therapeutics，and future prospective ［J］. Oncol Res，2025，34（1）：7.
［3］	Wild JB，Thrush S，Vidya R. What can national registry data tell us about occult breast cancer？［J］. Chin Clin Oncol，2019，8（S1）：S15.
［4］	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南-2025［M］. 北京：人民卫生出版社，2025.
［5］	庄梓林，聂燕. 美国国立综合癌症网络临床实践指南：乳腺癌诊疗（2024. V5）解读［J］. 临床外科杂志，2025，33（1）：11-14.
［6］	Wang XY，Fan LW，Yan WX，et al. Axillary lymph node metastasis as the first manifestation of male occult breast cancer：a case report ［J］. Medicine （Baltimore），2018，97（50）：e13706.
［7］	Cardoso F，Kyriakides S，Ohno S，et al. Early breast cancer：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up ［J］. Ann Oncol，2019，30（8）：1194-1220.
［8］	Guo YW，Yu P，Liu ZM，et al. Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer：a systematic review and meta-analysis ［J］. PLoS One，2017，12（4）：e0174843.
［9］	Giordano SH. Breast cancer in men ［J］. N Engl J Med，2018，378（24）：2311-2320.
［10］	Walker GV，Smith GL，Perkins GH，et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis ［J］. Cancer，2010，116（17）：4000-4006.
［11］	Early Breast Cancer Trialists' Collaborative Group （EBCTCG）. Radiotherapy to regional nodes in early breast cancer：an individual patient data meta-analysis of 14 324 women in 16 trials ［J］. Lancet，2023，402（10416）：1991-2003.
［12］	Ge I，Erbes T，Juhasz-Böss I. Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence：a systematic review of the literature ［J］. Arch Gynecol Obstet，2022，306（4）：943-957.
［13］	丁颖，龙汉安，叶入裴，等. 男性乳腺癌与女性乳腺癌临床病理学特征对比分析［J］. 西南医科大学学报，2019，42（1）：40-43.
［14］	Johnston SRD，Toi M，O'Shaughnessy J，et al. Abemaciclib plus endocrine therapy for hormone receptor-positive，HER2-negative，node-positive，high-risk early breast cancer （monarchE）：results from a preplanned interim analysis of a randomised，open-label，phase 3 trial ［J］. Lancet Oncol，2023，24（1）：77-90.
［15］	Piezzo M，Cocco S，Caputo R，et al. Targeting cell cycle in breast cancer：CDK4/6 inhibitors ［J］. Int J Mol Sci，2020，21（18）：6479.
［16］	中国药学会医院药学专业委员会，《乳腺癌CDK4/6抑制剂药物相互作用管理专家共识》工作组. 乳腺癌CDK4/6抑制剂药物相互作用管理专家共识（2024版）[J].中国医院药学杂志，2025，45（22）：2545-2555，2611.
［17］	Xu B，Zhang Q，Zhang P，et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer：a randomized，phase 3 trial ［J］. Nat Med，2021，27（11）：1904-1909.
［18］	Montagna E，Bagnardi V，Rotmensz N，et al. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation ［J］. Breast Cancer Res Treat，2011，129（3）：867-875.

Please choose a citation manager

Content to export

Male occult breast cancer: one case report

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 8

References 18

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Male occult breast cancer: one case report

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 8

References 18

Related Articles 0

Recommended Articles

Metrics

Comments